FDA Fast-Tracks Psychedelic Drug Research Following Trump Order

The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, a move following President Trump's executive order to facilitate approval. This marks a significant shift towards supporting psychedelic-based medicines for treatment-resistant mental health conditions.

Coverage

• FDA moves to fast-track review of psilocybin and methylone for mental health - CNN
• FDA moves to fast-track review of 3 psychedelic drug studies
• FDA fast-tracks psychedelic drug research following Trump executive order
• The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics

CrossCut News